Co-Authors
This is a "connection" page, showing publications co-authored by Ennio Favalli and Piercarlo Sarzi-Puttini.
Connection Strength
0.774
-
Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clin Exp Rheumatol. 2021 May-Jun; 39(3):695.
Score: 0.233
-
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun. 2021 01; 116:102545.
Score: 0.226
-
Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):804-809.
Score: 0.182
-
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017 Sep; 16(9):911-924.
Score: 0.045
-
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):660-665.
Score: 0.045
-
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
Score: 0.044